Kamada Projects Strong Double-Digit Revenue and EBITDA Growth for 2026
Summary
Kamada Ltd. announced optimistic 2026 financial guidance, projecting double-digit revenue and adjusted EBITDA growth driven by organic expansion, while also affirming its 2025 targets.
Key Events
-
2026 Financial Guidance
Kamada forecasts 2026 revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million.
-
Double-Digit Organic Growth
The 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA (mid-point basis), based solely on continued organic growth.
-
2025 Guidance Affirmed
The company reaffirmed its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with approximately $75 million in year-end cash.
-
Strategic Expansion
Growth is expected from expanding the commercial product portfolio, launching biosimilars, extending distribution to the MENA region, and increasing plasma collection.
Analysis
Kamada Ltd. has provided robust financial guidance for 2026, forecasting significant double-digit increases in both revenues and adjusted EBITDA, driven by organic growth. This positive outlook, coupled with the affirmation of its 2025 financial targets and a healthy cash position, signals strong operational performance and strategic execution. The company's ability to project continued growth despite a reduction in GLASSIA royalty payments highlights the strength and diversification of its commercial product portfolio and plasma collection operations. Investors should view this guidance as a strong indicator of future profitability and market expansion.
At the time of this filing, KMDA was trading at $7.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $428.6M. The 52-week trading range was $5.54 to $9.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.